Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138
Debt
Debt-to-Equity Ratio0.35
Current Ratio8.49
Quick Ratio8.49
Price-To-Earnings
Trailing P/E Ratio-2.47
Forward P/E Ratio-4.03
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book5.62
Profitability
EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-156.68%
Return on Assets-83.59%
Miscellaneous
Employees16
Outstanding Shares14,240,000
Market Cap$166.23 million
Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions
What is Eiger Biopharmaceuticals' stock symbol?
Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."
How were Eiger Biopharmaceuticals' earnings last quarter?
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) posted its quarterly earnings results on Friday, August, 10th. The biotechnology company reported ($0.82) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.82). View Eiger Biopharmaceuticals' Earnings History.
When is Eiger Biopharmaceuticals' next earnings date?
What price target have analysts set for EIGR?
7 brokers have issued 1 year price objectives for Eiger Biopharmaceuticals' shares. Their forecasts range from $24.00 to $53.00. On average, they anticipate Eiger Biopharmaceuticals' stock price to reach $32.7143 in the next year. This suggests a possible upside of 172.2% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.
What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.
Who are some of Eiger Biopharmaceuticals' key competitors?
Some companies that are related to Eiger Biopharmaceuticals include Vericel (VCEL), Voyager Therapeutics (VYGR), Scholar Rock (SRRK), NanoString Technologies (NSTG), La Jolla Pharmaceutical (LJPC), Replimune Group (REPL), Nightstar Therapeutics (NITE), Gritstone Oncology (GRTS), PDL BioPharma (PDLI), MeiraGTx (MGTX), Sutro Biopharma (STRO), Adverum Biotechnologies (ADVM), Translate Bio (TBIO), Cellular Biomedicine Group (CBMG) and CASI Pharmaceuticals (CASI).
Who are Eiger Biopharmaceuticals' key executives?
Eiger Biopharmaceuticals' management team includes the folowing people:
- Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 54)
- Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 55)
- Mr. James A. Welch, Chief Financial Officer (Age 60)
- Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 53)
- Mr. James P. Shaffer, Chief Bus. Officer (Age 51)
Who are Eiger Biopharmaceuticals' major shareholders?
Eiger Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.36%). Company insiders that own Eiger Biopharmaceuticals stock include Jeffrey S Glenn and Joanne Quan. View Institutional Ownership Trends for Eiger Biopharmaceuticals.
Which institutional investors are buying Eiger Biopharmaceuticals stock?
How do I buy shares of Eiger Biopharmaceuticals?
Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eiger Biopharmaceuticals' stock price today?
One share of EIGR stock can currently be purchased for approximately $12.02.
How big of a company is Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals has a market capitalization of $166.23 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.
What is Eiger Biopharmaceuticals' official website?
How can I contact Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]
MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
